In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read More
In a nutshell This trial was carried out to examine the effectiveness and safety profile of pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of classical Hodgkin lymphoma (cHL) that has relapsed and is refractory (resistant to drug treatment). The authors found that...
Read More
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...
Read More
In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...
Read More
In a nutshell This study aimed to investigate the real-world safety and effectiveness of brentuximab vedotin (BV) and bendamustine before stem cell transplant (SCT) for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective as...
Read More
In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...
Read More
In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...
Read More
In a nutshell The study evaluated outcomes of the combination of carfilzomib (Kyprolis; K), dexamethasone (Decadron; d), and daratumumab (Darzalex; D) in patients with relapsed or refractory (r/r) multiple myeloma (MM). The authors found that KdD was safe and effective to improve progression-free survival (PFS) in such patients compared to...
Read More
In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...
Read More
In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia. This study concluded that this treatment combination is safe and effective as a salvage treatment...
Read More
In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...
Read More
In a nutshell This study compared the effectiveness of CAR-T treatment for patients with diffuse large B cell lymphoma (DLBCL). The authors found that while a significant number of all patients benefitted from the treatment, some patients were more likely to benefit from it than others. Some background During initial treatment for DLBCL,...
Read More
